PCORI funding to focus on a national research data network

The Patient-Centered Outcomes Research Institute has announced $5 million in funding for a demonstration project of its national clinical research data network.

PCORI, a not-for-profit organization created under the Affordable Care Act to fund comparative-effectiveness research, approved an initial $93.5 million funding round in December 2013 to build the data network--PCORnet.

Initial funding went to 18 research networks focused on patients with specific health conditions who are interested in sharing health data; and 11 clinical data research networks with healthcare systems collecting data during care delivery.

The demonstration project will be completed in two phases. In the first phase, PCORI will award up to $1 million over one year to allow PCORnet sites to collaborate with health system leaders in an effort to identify and prioritize data-driven research activities. During phase two, PCORI will award up to $4 million to fund as many as five one-year research studies on those priority areas. The project will focus on adding value to multiple PCORnet health systems and leveraging data resources with or without additional health system data.

The organization plans to release requirements for a limited competition in May, with applications due in June.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.